Orphan Drugs Won a Zero-Tariff Island in July — and Insmed's 15% Surge Was Volume, Not Price

Insmed reported third-quarter revenue of $524.4 million on Oct. 29, 2026, up 268% from $142.3 million a year earlier, and lifted both of its 2026 guidance ranges. BRINSUPRI did all the work: $400.1 million of net product revenue, 29% above the second quarter and 76% of total company revenue. ARIKAYCE added $124.4 million, up 9% from a year earlier. The company still lost $100.3 million, or $0.46 a share, because research spending ran at $270.0 million, or 51.5% of revenue.

Management lifted the low end of both ranges by $100 million and $10 million and left the high ends exactly where they were. That is not a beat. It says the company is more confident about the run rate it already has, not that the market should expect a larger number. The 15% move therefore repriced confidence rather than the forecast, and confidence was the variable that had been falling for ten months.

BRINSUPRI has carried an $88,000 annual list price since its August 2025 approval, and management guides 2026 gross-to-net in the mid-to-high 20s, which puts net revenue near $65,000 a patient-year. Divide the $400.1 million third-quarter run rate by that net price and the quarter implies roughly 24,600 patients on paid therapy. Nothing in the quarter was a price action. Everything was a volume action.

The margin structure confirms it. Gross margin reached 85.1%, up from 79.4% a year earlier, while Insmed cut selling and administrative expense to 48.2% of revenue from 130.9% a year before. Each incremental patient now arrives at an 85% gross margin against a cost base that barely moves, which is how a company with a 51.5% research ratio and a $100.3 million net loss is still three quarters from cash generation.

Insmed does not name its customers, but the concentration disclosure tells the story. Four customers accounted for 92% of nine-month gross product revenue in 2026, up from 71% a year earlier, and BRINSUPRI reaches patients through a comprehensive specialty pharmacy network. The marginal patient therefore passes through a short chain of specialty distributors and specialty pharmacies before anyone is paid.

The policy backdrop is what makes orphan volume defensible. The Section 232 proclamation of April 2, 2026 set a zero ad valorem tariff on drugs and associated ingredients whose approved indications are all designated as orphan under the Orphan Drug Act, took effect at 12:01 a.m. EDT on July 31, 2026, and left 15% for Japanese, European, Korean, Swiss and Liechtenstein goods and 100% for the remainder of the patented pharmaceutical trade.

Both of Insmed's marketed products sit inside the carve-out. ARIKAYCE has carried FDA orphan designation for nontuberculous mycobacterial lung disease since 2013, and brensocatib holds orphan designation for bronchiectasis, which is the indication for which BRINSUPRI was approved in August 2025. The honest limit on this point: Insmed's quarterly filings do not disclose how much of its own supply chain crosses a border, so the shelter explains the structure of the market rather than the quarter's gross margin. What it does do is guarantee that the cost line of an orphan portfolio is insulated from the tariff pressure that a non-orphan competitor faces, and Insmed's Japan launch on Oct. 19, 2026 puts it into a market with roughly 150,000 diagnosed bronchiectasis patients.

The Medicare side runs the same way. Orphan drugs are exempt from Medicare price negotiation, which is one reason an $88,000-a-year inhaled tablet can hold a net price near $65,000 without a negotiated reset. The one visible leak is the Inflation Reduction Act's small-manufacturer provision: management said the coverage cost Insmed bears rises from 1% in 2026 to 5% in 2027 on its way to 20% by 2031, and that it will widen ARIKAYCE's gross-to-net next year.

The rally had to overcome a ten-month slide. Brensocatib failed a mid-stage study in chronic rhinosinusitis on Dec. 17, 2025 and the shares fell about 17% to roughly $165; Insmed formally disclosed the discontinuation of that indication in April 2026. On Oct. 5, 2026 the company said chief financial officer Sara Bonstein would leave effective Oct. 30, 2026 without naming a successor, and the shares fell 8%. Between Mar. 31 and June 30, 2026, market capitalization fell from $35.2 billion to $23.2 billion, a 34% drawdown in the quarter when BRINSUPRI revenue was compounding fastest.

One session reversed the trend. The shares closed at $96.98 on Oct. 29 and at $111.59 on Oct. 30, a 15% one-day gain on a floor raise, and they held $112.58 on Nov. 2. The board also added a new audit committee member on Oct. 16, 2026, in the same month the finance seat emptied.

Three things undercut the bull case, and one of them is valuation. The quarter missed the consensus loss of $0.38 a share. The chief financial officer seat has been empty since Oct. 30, 2026 at a company guiding to $1.8 billion of revenue while running a three-asset Phase 3 program. And at roughly $25.0 billion of enterprise value the shares trade at 16.5 times trailing revenue, against 7.6 times for United Therapeutics, 5.6 times for Regeneron and 3.7 times for Ultragenyx, all of which are either profitable or growing far more slowly.

Orphan drugs now sit in a policy shelter most of the industry lacks: a zero Section 232 tariff, exclusion from Medicare price negotiation, and a price set once and defended because the treated population is small enough to need every dollar of access support. Insmed's quarter shows what that shelter is worth in cash terms — $524.4 million of revenue, an 85.1% gross margin and a selling and administrative cost ratio that converts volume into operating leverage while the research bill keeps climbing. What the quarter does not show is that the shelter survives the portfolio's next major approval. One mixed-indication product, one empty finance seat and one revenue line still waiting on a Phase 3 readout can each take the re-rating back.